


Cross-genotype AR3-specific neutralizing antibodies confer long-term protection in injecting drug users after HCV clearance

Graphical abstract



Authors

Sabrina J. Merat, Camille Bru, Dorien van de Berg, ..., Hergen Spits, Tim Beaumont, Janke Schinkel

Correspondence

tbeaumont@aimmtherapeutics.com (T. Beaumont), j.schinkel@amsterdamumc.nl (J. Schinkel)

Lay summary

Although effective treatments against hepatitis C virus (HCV) are available, 500,000 people die from liver disease caused by HCV each year and approximately 1.75 million people are newly infected. This could be prevented by a vaccine. To design a vaccine against HCV, more insight into the role of antibodies in the protection against HCV infection is needed. In a cohort of injecting drug users, we found that antibodies interfering with virus cell entry, and recognizing multiple HCV genotypes, conferred long-term protection against chronic HCV infection.

Highlights

- HCV clearance is associated with a high number of cross-genotype specific antibodies.
- Antigenic region 3 (AR3) is the dominant epitope recognized by the antibodies.
- AR3-specific antibodies neutralized HCV pseudoparticles and cell culture viruses.
- A large number of clearers develop antibodies targeting antigenic region 4 (AR4).
- AR4-specific antibody AT1618 also neutralized neutralization-resistant variants.



Cross-genotype AR3-specific neutralizing antibodies confer long-term protection in injecting drug users after HCV clearance

Sabrina J. Merat¹, Camille Bru^{1,†}, Dorien van de Berg^{1,†}, Richard Molenkamp², Alexander W. Tarr^{3,4}, Sylvie Koekkoek², Neeltje A. Kootstra⁵, Maria Prins^{6,7}, Jonathan K. Ball^{3,4}, Arjen Q. Bakker¹, Menno D. de Jong², Hergen Spits¹, Tim Beaumont^{1,*}, Janke Schinkel^{2,*}

¹AIMM Therapeutics, Amsterdam, the Netherlands; ²Department of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands; ³School of Life Sciences, The University of Nottingham, Nottingham, UK; ⁴NIHR Nottingham BRC, Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK; ⁵Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands; ⁶Public Health Service of Amsterdam, Amsterdam, the Netherlands; ⁷Department of Infectious Diseases, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands

See Editorial, pages 9–11

Background & Aims: In order to design an effective vaccine against hepatitis C virus (HCV) infection, it is necessary to understand immune protection. A number of broadly reactive neutralizing antibodies have been isolated from B cells of HCV-infected patients. However, it remains unclear whether B cells producing such antibodies contribute to HCV clearance and long-term immune protection against HCV.

Methods: We analysed the B cell repertoire of 13 injecting drug users from the Amsterdam Cohort Study, who were followed up for a median of 17.5 years after primary infection. Individuals were classified into 2 groups based on the outcome of HCV infection: 5 who became chronically infected either after primary infection or after reinfection, and 8 who were HCV RNA negative following spontaneous clearance of ≥ 1 HCV infection (s). From each individual, 10,000 CD27+IgG+B cells, collected 0.75 year after HCV infection, were cultured to characterize the antibody repertoire.

Results: Using a multiplex flow cytometry-based assay to study the antibody binding to E1E2 from genotype 1 to 6, we found that a high frequency of cross-genotype antibodies was associated with spontaneous clearance of 1 or multiple infections ($p = 0.03$). Epitope specificity of these cross-genotype antibodies was determined by alanine mutant scanning in 4 individuals who were HCV RNA negative following spontaneous clearance of 1 or multiple infections. Interestingly, the cross-genotype antibodies were mainly antigenic region 3 (AR3)-specific and showed cross-neutralizing activity against HCV. In addition to AR3 antibodies, 3 individuals developed antibodies recognizing antigenic region 4, of which 1 monoclonal antibody showed cross-neutralizing capacity.

Keywords: Injecting drug user; HCV infection; Spontaneous clearance; Memory B cell; Broadly neutralizing antibody.

Received 2 March 2018; received in revised form 29 January 2019; accepted 12 February 2019; available online 21 February 2019

* Corresponding authors. Addresses: AIMM Therapeutics, Meibergdreef 59, 1105 BA Amsterdam, the Netherlands; Tel.: +31 20 5662145 (T. Beaumont), or K1-121 Academic Medical Center Meibergdreef 9 1105 AZ Amsterdam, the Netherlands; Tel.: +31 20 5665619 (J. Schinkel).

E-mail addresses: tbeaumont@aimmtherapeutics.com (T. Beaumont), j.schinkel@amsterdamumc.nl (J. Schinkel).

[†] Camille Bru and Dorien van de Berg contributed equally to this work.

^{*} Tim Beaumont and Janke Schinkel contributed equally as senior authors.

Conclusions: Together, these data suggest that a strong B cell response producing cross-genotype and neutralizing antibodies, especially targeting AR3, contributes to HCV clearance and long-term immune protection against HCV.

Lay summary: Although effective treatments against hepatitis C virus (HCV) are available, 500,000 people die from liver disease caused by HCV each year and approximately 1.75 million people are newly infected. This could be prevented by a vaccine. To design a vaccine against HCV, more insight into the role of antibodies in the protection against HCV infection is needed. In a cohort of injecting drug users, we found that antibodies interfering with virus cell entry, and recognizing multiple HCV genotypes, conferred long-term protection against chronic HCV infection.

Crown Copyright © 2019 Published by Elsevier B.V. on behalf of European Association for the Study of the Liver. All rights reserved.

Introduction

Hepatitis C virus (HCV) is one of the major global public health problems, with 71 million chronically infected people worldwide, which results in 350,000 to 500,000 liver-related deaths per year.¹ Current direct-acting antiviral (DAA) treatment is very effective in clearing infection.² However, despite high DAA efficacy, treatment alone is unlikely to eliminate HCV by the year 2030 as envisioned by the World Health Organization (WHO),¹ since treated individuals may become reinfected if exposure continues. Moreover, worldwide, most of the HCV-infected individuals are unaware of their HCV status because of the prolonged asymptomatic nature of HCV infection and limited access to diagnostic tests.³ In addition, as a result of the high cost of treatment, a large proportion of the HCV-infected individuals are left untreated.³ Therefore, for the global elimination of HCV, a preventive vaccine is urgently needed.

Development of a protective vaccine against HCV seems feasible, since spontaneous clearance of the virus without antiviral therapy occurs in 25 to 40% of individuals after primary infection⁴ and in 30 to 60% of those who are reinfected following clearance of a primary infection.⁵ While clearance of HCV infection has been associated with strong and broad T cell

responses,^{6,7} little is known about the role of antibodies in spontaneous clearance of HCV infection and protection upon re-exposure.

HCV clearance has been associated with a neutralizing antibody response against HCV E1E2 glycoproteins during the early phase of infection.^{8,9} In addition, a number of broadly neutralizing antibodies have been isolated from B cells of chronically infected individuals. In general, they target 1 of 3 epitopes which are located in or around the CD81 binding site: epitope I (amino acids 412–423), epitope II (amino acids 434–446) and domain B (amino acids 523–535).^{10–12} Interestingly, broadly neutralizing antibodies targeting epitope I or epitope II (AP33, HC84.26) protected humanized mice against HCV genotype 1b infection.^{13,14} It has also been shown that AR3A and AR3B antibodies targeting both epitope II and domain B, jointly referred to as antigenic region 3 (AR3), protected mice against HCV infection from isolate H77 (genotype 1a) and isolate J6 (genotype 2a) in combination with AR4A, an antibody recognizing antigenic region 4 (AR4).^{15–17} However, whether such broadly neutralizing antibodies contribute to spontaneous clearance and long-term immune protection in humans with ongoing exposure remains unanswered.

The Amsterdam Cohort Study (ACS) among drug users (DU), is a prospective cohort study investigating human immunodeficiency virus (HIV) and HCV infections, in which serum, peripheral blood mononuclear cells (PBMCs), and socio-demographic and risk behavioural data are collected regularly.¹⁸ The ACS-DU cohort started in 1985 and came to an end in 2016, making it a unique cohort with one of the longest follow-up periods recorded in DUs globally.¹⁹ Importantly, all ACS participants who are injecting drug users (IDU) are, most likely, frequently (re-)exposed to HCV, since 65% reported at least weekly injecting drug use at enrolment in the cohort, with a baseline HCV antibody prevalence of 82% and an incidence of up to 28 primary infections per 100 person-years among IDU.²⁰ Such a well-characterized cohort of highly exposed individuals with a long follow-up presents a unique opportunity to study the role of broadly neutralizing antibodies in the spontaneous clearance of HCV infection and protection upon re-exposure.

Herein, we studied the frequency, cross-reactivity and epitopes of HCV E1E2 specific antibodies produced by memory B cells from ACS participants. We found that the frequency of HCV specific cross-genotype antibodies, targeting mainly AR3 and AR4, was associated with spontaneous clearance of ≥ 1 HCV infection(s) and absence of HCV RNA at the end of the study period.

Material and methods

Participants

Individuals were selected from the ACS-IDU. After giving written informed consent, ACS participants visited the Amsterdam Health Service every 4 to 6 months, where blood was drawn for laboratory testing, PBMCs were stored and participants completed a standardized questionnaire on risk behaviour.¹⁸ Our study relies in part on self-reports, which have been shown to be a valid method for measuring behavioural variables in our cohort, where social desirability does not play an important role.²¹

For the study presented here, out of 106 individuals with an acute or recent HCV infection we selected those with at least 5 years of follow-up after primary infection, with available PBMCs. Acute primary infection was defined by seroconversion

for HCV antibodies (AxSym HCV version 3.0; Abbott) during follow-up.²² Recent infection was assumed when at cohort entry HCV antibodies were already present in individuals who had started injecting drugs less than 2 years before. We excluded individuals who were HIV-seropositive or positive for HBV surface antigen (AxSym HBsAg, Abbott) at the time of HCV infection.

For seroconverters, the date of the infection was estimated by calculating the midpoint between the last HCV seronegative visit and the first HCV seropositive visit. The date of infection for the recent infections was estimated as the midpoint between the start of injecting drugs and cohort entry.²²

HCV viremia was determined for these individuals at yearly intervals using a transcription-mediated amplification assay with a detection limit of 5 IU/ml (Versant; Siemens Medical Solutions Diagnostics). If HCV RNA was detected, genotyping was performed by sequencing the NS5B region.²³ Clearance was defined as being HCV RNA negative at 2 subsequent time points. After clearance, in some individuals, reinfection was documented, as evidenced by at least 1 HCV RNA positive time point during follow-up following clearance of an earlier infection. Chronic infection was defined as continuous viremia for at least 2 years after the estimated date of (re)infection. This study was approved by the Medical Ethical Committee of the AMC and informed consent was obtained from all participants. HCV genotype, HBV status and HIV status are summarized in [Table S1](#).

B cell isolation and cultures

Frozen PBMCs were obtained and CD27+IgG+B cells were immortalized as described previously.²⁴ In brief, B cells were isolated and, after stimulation, the cells were transduced with a retroviral vector containing the transgenes BCL6, BCL-xL and green fluorescent protein as marker gene. Transduced B cells were maintained in culture with gamma-irradiated CD40 Ligand expressing L-cells and recombinant mouse interleukin-21. The transduced B cells secrete immunoglobulins (antibodies) into the culture supernatant.

Multiplex flow cytometry assay

To determine the breadth of the antibodies, we performed a multiplex flow cytometry assay as described previously.²⁵ In brief, antibodies present in B cell supernatants were incubated with a mix of fluorescently barcoded 293 T/17 cells (ATCC) transfected with full-length E1E2 derived from 6 HCV genotypes (Supplementary material and methods). After addition of the secondary polyclonal goat anti-human IgG-PE antibody (Southern Biotech), the fluorescence was measured using a FACSCanto™ II flow cytometer (BD Biosciences). To determine E1E2 antibody binding, the value obtained for binding to E1E2 transfected cells was subtracted from the value obtained for binding to non-transfected cells and normalized by using the average of the 7 negative antibody controls. The cut-off value for binding was based on values of 882 B cell supernatants from 3 HCV uninfected individuals ([Fig. S1, Supplementary material and methods](#)).

Enzyme-linked immunosorbent assay

To determine the binding characteristics of the antibodies, enzyme-linked immunosorbent assays (ELISA) were performed as described previously.²⁶ In brief, plates were coated either with the HIS-tagged E2 ectodomain (Supplementary material

and methods) or with *Galanthus nivalis* lectin on which E1E2 protein containing 293 T/17 cell lysate was captured. Then, antibodies present in B cell supernatant were added and binding was detected by horseradish peroxidase-conjugated polyclonal goat anti-human IgG (Jackson). Optical density (OD) at 450 nm was measured with an EnVision Multilabel Reader (PerkinElmer).

HCV pseudoparticle neutralization

The neutralizing activity of antibodies was determined using the HCV pseudoparticle (HCVpp) system based on luciferase reporter gene activity (Supplementary material and methods).

HCV cell culture neutralization

Neutralization activity of antibodies was determined using the HCV cell culture (HCVcc) system as described previously.^{27,28} The detailed procedure is described in the supplementary material and methods.

Antibody sequencing

The variable regions of the antibody heavy and light chain from the cross-genotype B cells were sequenced as described previously.²⁹ In brief, total RNA was isolated from B cells and after generation of cDNA, the cDNA from the heavy and light chain were specifically amplified by PCR. Finally, the sequences were obtained by Sanger sequencing using BDT reagents (Thermo Fisher Scientific) and were submitted to the IMG/QUEST database to assess V(D)J usage and somatic hypermutation status.³⁰

Data analysis

Data were analysed using Prism software (GraphPad). Statistical comparison between categories was performed using a 1-tailed Mann-Whitney *U* test, as we hypothesized that cross-genotype antibodies were more frequently present in individuals who spontaneously cleared infection(s) (software package SPSS, v. 19.09, IBM). Flow cytometry data were analysed using FlowJo software (FlowJo).

For further details regarding the materials and methods used, please refer to the CTAT table and supplementary information.

Results

Characteristics of the study population

Thirteen cohort participants with acute or recent HCV infection met the inclusion criteria for this study. The median age of the selected individuals was 29 years (interquartile range [IQR] 23–33) at the time of HCV infection (Table 1). The median follow-up time of these individuals after primary HCV infection was 17.5 years (IQR 11.7–18.9). The individuals were classified into 2 groups based on the outcome of HCV infection: (i) individuals who became chronically infected (CHRs; n = 5) either after primary infection (CHR1-3), or after HCV reinfection (CHR 4–5); (ii) individuals who cleared ≥1 HCV infections and were HCV RNA negative at the end of follow-up (CL1-8). All individuals who cleared the infection were presumably re-exposed to HCV as they continued injecting drugs for a median of 5.9 years after primary infection during a time period (1986–1994) of

Table 1. Demographics and clinical characteristics.

Subject ID	Type of HCV infection(s)	Age*, (yr)	Gender	Follow-up #, (yr)	Duration of injecting drug use#, (yr)	HCV sero-conversion	Calendar year of infection	Timepoint of PBMC collection (yr)
CHR1	Chronic upon primary	34	M	12	4.4	Sc	1989	1.12 [#]
CHR2	Chronic upon primary	21	F	11	0.2	Sc	1988	1.18 [#]
CHR3	Chronic upon primary	47	M	17	11.9	Sc	1993	1.05 [#]
CHR4	Chronic upon reinfection	24	M	21	13.2	Rc	1989	0.81 [#]
CHR5	Chronic upon reinfection	29	F	18	4.9	Rc	1986	4.33 [#] 1.19 [§]
CL1	No reinfection	29	F	18	6.6	Rc	1992	0.47 [#]
CL2	Cleared multiple infections	23	F	17	7.5	Rc	1989	0.13 [#]
CL3	Cleared multiple infections	39	M	19	2.1	Sc	1990	0.43 [#]
CL4	Cleared multiple infections	20	F	19	5.3	Rc	1989	0.59 [#]
CL5	No reinfection	29	F	9	3.2	Rc	1988	0.75 [#]
CL7	Cleared multiple infections	23	M	23	14.5	Rc	1986	9.36 [#] 2.51 [§]
CL8	Cleared multiple infections	33	F	14	6.4	Rc	1989	0.93 [#] 0.59 ⁺
CL9	Cleared multiple infections	26	M	7	4.9	Rc	1987	5.28 [#] 0.54 [§]
Median		29		17.5	5.3		1989	0.75

CHR: Individuals who ultimately became chronically infected; CL: Individuals who, at the end of study follow-up, were HCV RNA negative; Chronic upon primary: individuals who became chronically infected following primary infection; Chronic following reinfection: individuals who became chronically infected following reinfection; Cleared multiple infections: individuals who spontaneously cleared both primary infection and reinfection; No reinfection: individuals who spontaneously cleared primary infection without a documented reinfection. *At the estimated date of infection, #after the estimated date of infection and §after estimated time of reinfection. HCV, hepatitis C virus; PBMC, peripheral blood mononuclear cell; Sc, seroconverter; Rc, recent.

A

Subject information			Number of B cells specific for E1E2						Frequency	
Subject ID	Genotype of primary infection	Reinfection/genotype	H77 (1a)	AMS.2b.21 (2b)	AMS.3a.26 (3a)	UKN4 11.1 (4a)	UKN5.15.7 (5)	UKN6.5.340 (6)	Total	per 10,000 B cells
CHR1	3	No	5	0	14	7	0	0	19	18.5
CHR2	1	No	40	2	0	4	0	1	40	38.9
CHR3	1	No	3	1	0	2	0	0	4	3.9
CHR4	ND	Yes/3	0	0	0	15	0	0	15	14.6
CHR5	1	Yes/3	2	0	1	0	0	0	3	2.9
CL1	3	No	70	11	65	72	25	28	78	75.8
CL2	ND	Yes/1	98	10	78	108	16	11	111	107.9
CL3	ND	Yes/ND	23	0	24	21	0	0	24	23.3
CL4	ND	Yes/ND	3	1	3	3	0	2	3	2.9
CL5	ND	No	2	0	0	2	0	0	4	3.9
CL7	ND	Yes/ND	79	29	53	56	55	45	83	80.7
CL8	ND	Yes/ND	9	1	6	6	0	4	10	9.7
CL9	ND	Yes/ND	2	0	0	2	0	0	2	1.9
Median (CHR)	NA	NA	3	0	0	4	0	0	15	14.6
Median (CL)	NA	NA	16	1	15	13.5	0	3	17	16.5




Fig. 1. Frequency and cross-reactivity of E1E2 specific antibodies. The number and the cross-reactivity of E1E2 specific antibodies were studied in CHRs or in CLs. Antibodies present in B cell supernatant of 35 cell per well mini-cultures (total of 10,290 CD27+IgG+B cells) were tested for binding to E1E2 derived from 6 different genotypes using a multiplexed flow cytometry assay. (A) From each individual (in row), the number and frequency of antibodies specific for E1E2 from genotype 1 to 6/isolate (in column) are indicated. The grey filling colors indicate the number of E1E2 antibodies targeting E1E2 of a particular genotype: white indicates the lowest number of antibodies and grey dark the highest. For each individual, the highest number of antibodies binding E1E2 from a particular genotype was bolded and underlined. (B) The pie chart with grey scale represents cross-reactivity of the E1E2 specific antibodies from each participant. CHR: Individuals who ultimately became chronically infected; CLs: Individuals who, at the end of study follow-up, were HCV RNA negative. HCV, hepatitis C virus; NA, not applicable; ND, not determined.

extremely high HCV incidence (10–28 per 100 person-years) in this cohort.²⁰ Frequent re-exposure was also evidenced by the occurrence of ≥ 1 reinfections, which were documented in 8 of 13 individuals. Characteristics of all 13 individuals are summarized in Table 1.

High frequencies of cross-genotype antibodies in CLs

From each participant, 7 to 15 million PBMCs were available that had been collected 0.75 year (IQR 0.54–1.12) after HCV infection (Table 1). From these PBMCs, CD27+IgG+B cells were purified and subsequently immortalized.²⁴ A total of 10,290 cells per individual were cultured as mini-cultures at a density of 35 cells per well. Antibodies secreted in the B cell supernatant were analysed for binding to 293 T cells transfected with full-length E1E2 from HCV genotypes 1a, 2b, 3a, 4, 5 and 6, using the multiplexed flow cytometry assay as described before.²⁵

At a density of 35 cells per well, the percentage of positive wells was below or equal to 37%. We, therefore, assumed based on the Poisson's distribution, that only 1 out of the 35 cells produced E1E2 specific antibodies. The median frequency of E1E2 specific antibodies in the B cell repertoire was 14.6 antibodies per 10,000 CD27+IgG+B cells for CHRs (IQR 3.9–18.5) and 16.5 antibodies per 10,000 CD27+IgG+B cells for CLs (IQR 3.6–77) (Fig. 1A). Although the frequencies did not differ between the groups, the antibodies from CHRs were mainly genotype-specific and directed against the genotype of the ongoing infection. This confirmed findings by Tarr *et al.*, who described the relationship between serum antibody reactivity and genotype of infection.³¹ Antibodies from CLs showed a much broader reactivity than CHR derived antibodies. The absolute number of antibodies recognizing at least 3 or more genotypes was significantly higher in CLs than CHRs (CLs: 13 (IQR 2.2–53.0) vs.




Fig. 2. Epitope binding of the cross-genotype antibodies from CLs. To determine the epitopes targeted by the cross-genotype antibodies, antibody binding was tested by ELISA using E1E2 mutants. Single alanine amino acid substitutions were introduced into the E1E2 sequence from isolate H77 at positions important for binding of broadly neutralizing antibodies in 4 described epitopes (epitope I, AR3/epitope II, AR3/domain B and AR4). Cell lysates from 293 T cells transfected with the alanine mutants of E1E2 were incubated on *Galanthus nivalis* lectin pre-coated wells before the antibody containing B cell supernatants from individuals CL1, CL2, CL3 and CL7 were added. The background was subtracted from the optical density value of each well, and the relative binding was calculated by dividing the value obtained with wild-type protein by the alanine mutant protein value. (A) The pie charts represent the distribution of epitopes targeted by all cross-genotype-specific antibodies from each individual, separately. (B) The colour filling indicates the relative binding level: black 0%–25%, grey 25%–50% and white 50%–150%. The E2 mutants were designated X123Y where

A

Subject	Minicultures	Epitope	AT	Isotype	VH gene	CDR3H (aa)	VL gene
CL1	E22	AR3	AT1638	IgG1	VH1.69	14	VL10.54
	J19	AR3	AT1640	IgG1	VH1.69	20	VK1.05
	B09	AR4	AT1644	IgG1	VH4.59 or 4.61	15	VK3.20
CL2	C09, G07	AR3	AT1637	IgG1	VH1.69	17	VK2.28
	H21, M22	AR3	AT1639	IgG1	VH1.69	21	VK4.1
	D19	AR4	AT1646	IgG1	VH1.03	23	VK3.20
	E22	AR4	AT1647	IgG1	VH3.07	25	VK1.39 or 1D.39
CL3	F12, K08	AR3	AT1642	IgG1	VH1.69	21	VL1.40
	F22	AR3	AT1645	IgG1	VH1.69	19	VL1.40
CL7	NA	AR3	AT1706	IgG1	VH3.30	20	VK3.15
	F10	AR3	AT1643	IgG1	VH1.69	22	VK1.5
	NA	AR4	AT1618	IgG1	VH3.23	19	VK1.5

B




Fig. 3. Characteristics of monoclonal cross-genotype antibodies from CLs. (A) Antibody heavy and light chain genes of 10 B cell clones that were isolated by single cell sorting of B cells from individuals CL1, CL2, CL3 and CL7, and 2 B cell clones (AT1706 and AT1618) from participant CL7 that were obtained after screening single B cell cultures for HCVpp neutralization activity. Gene analysis was done using the IMGT/V-QUEST database. (B) The cross-reactivity of the 12 monoclonal antibodies was confirmed by ELISA. First, the cell lysates of 293 T cells transfected with E1E2 from genotype 1 to 6 or non-transfected cells were captured on GNA pre-coated wells before antibodies present in B cell supernatants were added and detected using anti-human IgG conjugated horseradish peroxidase. The x-axis indicates the mean OD at 450 nm and the error bars represent 1 SD. Anti-RSV F antibody D25 was used as a negative control and anti-HCV AT12-009 as a positive control. The assay was performed in duplicate wells and repeated at least once. CLs: Individuals who, at the end of study follow-up, were HCV RNA negative. aa, amino acids; CDR, complementarity determining region; HCV, hepatitis C virus; HCVpp, HCV pseudoparticles; OD, optical density; VH, variable domain of the heavy chain; VL, variable domain of the light chain.

CHRs: 0 (IQR 0–1.9), $p = 0.03$, Fig. 1B and Fig. S2). Three out of 8 CLs had antibodies that recognized all 6 HCV genotypes with a median frequency of 3.9 per 10,000 CD27+IgG+B cells (IQR 3.4–14.6). Such broadly reactive antibodies were not detected in CHRs.

Cross-genotype antibodies from CLs predominantly target AR3

To further characterize cross-genotype antibodies from CLs, we selected 113 B cell cultures from CL1, CL2, CL3, and CL7, who had the highest frequency of cross-genotype antibodies (Fig. S3). To determine the epitopes targeted by these antibodies, we tested the antibodies secreted in the B cell supernatant by ELISA for binding to E2 alanine mutants in the 4 epitopes known to be recognized by broadly neutralizing HCV antibodies. Twelve alanine mutants were generated with mutations in epitope I (L413, G418 and W420), in AR3/epitope II (L441, F442 and Y443), in AR3/domain B (W529, G530 and D535) and in AR4 (R657, L692 and D698).^{16,32,33} Epitope specificity was determined by measuring the reduction in antibody binding to ≥ 1 alanine mutants from the panel. An epitope was considered to be specifically recognized if an alanine mutation in that epitope resulted in more than a 50% reduction of antibody binding compared to binding to wild-type E2.

In all 4 participants, the majority of the cross-genotype antibodies (82/113, 73%) were specific for AR3 (Fig. 2A) as binding to the AR3-specific mutants (F442A, G530A and D535A) was reduced by more than 50% (Fig. 2B). Interestingly, binding of a subset of AR3-specific antibodies was not strongly affected by the alanine mutation in residue 441, which is in contrast to recent data from Gopal *et al.* who showed that this L441A mutation affected all AR3 antibodies.³³ Furthermore, we observed that 3 antibodies (C03, E17 and M11) found in participant CL2 were specific for an epitope shared by epitope I and AR3, as was evident by the loss of binding to the mutant W420A. This finding was confirmed at the monoclonal B cell level (Fig. S4).

Besides antibodies specific to AR3, we observed that cross-reactive antibodies targeting AR4 were present in 3 CLs, as indicated by the decreased binding to the mutants R657A, L692A and D698A. Interestingly, these AR4-specific antibodies showed no or low binding to the soluble E2 ectodomain (Fig. S5). Finally, we did not find antibodies that recognized only epitope I or epitope II in any of the CLs.

Monoclonal cross-genotype antibodies from CLs are broadly neutralizing

Thus far, antibody characteristics were determined using supernatants of B cells cultured at a density of 35 cells per well and therefore the supernatants of those cultures could contain 34 irrelevant antibodies. Therefore, we analysed antibodies at the monoclonal B cell level to study the neutralizing potency of the antibodies in more detail. Focusing on cross-genotype antibodies against AR3 and AR4, 13 mini-cultures with different alanine mutant patterns were selected, of which B cell clones were generated by single cell sorting (Supplementary material and methods). Immunoglobulin genes of AR3 and AR4 binding B cell clones were sequenced and 10 unique antibody sequences were identified (Fig. 3A). In addition, 2 additional monoclonal antibodies (AT1706 and AT1618) were isolated, from participant CL7 who had the highest frequency of cross-genotype antibodies when screening directly 5,000 CD27+IgG+single cell cultures for HCVpp neutralization activity. All 12 antibodies were of the IgG1 isotype. In addition, the majority of AR3-specific antibodies (AT antibodies 1637–1640, 1642, 1643, 1645) used a VH gene of the VH1.69 family. These results are in line with our findings and those of others.^{15,26,34}

Next, we confirmed the cross-reactivity of the monoclonal antibodies by ELISA, using the panel of 8 E1E2 sequences from genotypes 1 to 6 (Fig. 3B). As expected from the mini-culture data, AT1644 and AT1645 were specific for sequences from only 3 different HCV genotypes, whereas all other antibodies bound to E1E2 from genotypes 1 to 6.

A

Antibody	H77 (1a)	AMS.1b.2 (1b)	AMS.3a.26 (3a)	AMS.4d.8 (4d)
AR3B	0.133	0.008	0.41	0.50
AR4A	0.286	0.071	0.48	2.24

B

Subject	Antibody	H77 (1a)	AMS.1b.2 (1b)	AMS.3a.26 (3a)	AMS.4d.8 (4d)
CL1	AT1638	0.097	0.036	0.19	>1.16
	AT1640	0.177	0.070	0.58	1.41
	AT1644	>4.62	>1.34	>4.62	>4.62
CL2	AT1637	0.088	0.018	0.14	0.60
	AT1639	0.121	0.036	0.21	1.33
	AT1646	>2.58	0.145	>2.58	1.16
	AT1647	>1.10	0.679	>1.10	>1.10
CL3	AT1642	0.349	0.041	0.76	0.83
	AT1645	>8.58	>2.43	0.82	5.72
CL7	AT1706	0.100	0.452	>1.36	0.45
	AT1643	0.329	1.216	0.30	>1.82
	AT1618	0.385	0.141	1.64	0.82

C

Antibody	UKNP2.4.1 (2)	UKNP3.1.2 (3)	UKN4.11.1 (4)	UKNP6.1.2 (6)
AR3B	9.05	0.90	0.80	1.61
AR4A	1.03	1.54	0.55	1.58

D

Subject	Antibody	UKNP2.4.1 (2)	UKNP3.1.2 (3)	UKN4.11.1 (4)	UKNP6.1.2 (6)
CL1	AT1638	ND	0.46	0.39	>1.38
	AT1640	0.86	1.08	0.50	0.58
	AT1644	ND	>4.02	>1.34	>4.02
CL2	AT1637	13.43	0.53	>0.40	0.53
	AT1639	>15	1.35	0.48	1.35
	AT1646	ND	>2.7	>1.75	>2.7
	AT1647	ND	>1.71	>0.82	>1.71
CL3	AT1642	ND	2.06	>1.14	>6.17
	AT1645	>15	>3.67	>2.43	>3.67
CL7	AT1706	ND	0.65	0.90	>1.95
	AT1643	9.79	>1.39	>1.82	>1.39
	AT1618	18.2	5.00	1.64	5.00

Fig. 4. Neutralization activity of cross-genotype antibodies from CLs in the HCVpp system. The neutralization capacity of the antibodies was tested using (A-B) a panel of 4 HCVpp from genotypes 1 to 4 and (C-D) a panel of 4 HCVpp resistant to antibody neutralization from genotype 2 to 6. Neutralization was determined by incubating HCVpp expressing E1E2 with a 2-fold serial dilution of antibody-containing B cell supernatants before inoculation on Huh-7 cells. The IC₅₀ in µg/ml was determined as the midpoint between the last concentration giving more than 50% neutralization and the first concentration giving less than 50% neutralization. The grey colours indicate the range of neutralization: an IC₅₀ <0.1 µg/ml (black), 0.1–1 µg/ml (dark grey), 1–10 µg/ml (light grey) and above 10 µg/ml or no 50% neutralization was observed (white). The genotype of the isolates is indicated between brackets. CLs: Individuals who, at the end of study follow-up, were HCV RNA negative. AR3B, antibody to antigenic region 3 domain B; AR4A, antibody to antigenic region 4; HCV, hepatitis C virus; HCVpp, HCV pseudoparticles; IC₅₀, 50% inhibitory concentration; ND, not done.

The neutralization capacity of the antibodies was tested using the HCVpp system expressing E1E2 from genotypes 1a, 1b, 3a and 4d. These HCVpp were all relatively sensitive to neutralization by AR3B and AR4A (Fig. 4A). Except for AT1644, which did not neutralize, all monoclonal antibodies neutralized ≥1 HCVpp with 10 antibodies showing broad cross-neutralization (Fig. 4B). All AR3-specific antibodies (AT antibodies 1637-1640,1642, 1643,1645 and 1706 – Fig. S6) neutralized HCVpp with a 50% inhibitory concentration (IC₅₀) range from 0.088 to 1.41 µg/ml (Fig. 4B), while the AR4-specific antibodies (AT1644, AT1646, AT1647 and AT1618 – Fig. S6) had IC₅₀ values above 0.1 µg/ml (Fig. 4B).

The neutralization capacity of the antibodies was further tested using a panel of 4 HCVpp which have been shown to be resistant to antibody-mediated neutralization (Fig. 4C).³⁵ Eight

out of 12 antibodies (AT antibodies 1637–1640,1642, 1643,1618 and 1706) neutralized ≥1 resistant HCVpp with an IC₅₀ range of 0.39 to 18.2 µg/ml (Fig. 4D). Of these antibodies, AT1640 and AT1618 neutralized all 8 HCV isolates (Fig. 4B and Fig. 4D). Importantly, by examining the combined neutralization profiles of the antibodies per participant, antibodies from 3 of the 4 individuals tested (CL1, CL2 and CL7) covered all tested HCVpp.

To confirm the neutralization capacity of the antibodies, AT antibodies were tested at 20 µg/ml for neutralization of HCVcc (isolate H77). Apart from AT1645, all AR3-specific antibodies (AT antibodies 1638-1640, 1643 and 1706) neutralized infection by more than 50% (Fig. 5A). In addition to AR3 specific antibodies, neutralization activity above 50% was observed for the AR4-specific antibody AT1618. These findings were consistent with the data obtained using HCVpp.




Fig. 5. Neutralization activity of cross-genotype antibodies from CLs in the HCVcc system. (A) Neutralization was determined by incubating HCVcc expressing E1E2 from isolate H77 with 20 μg/ml of purified antibodies before inoculation on Huh-7.5 cells. Anti-tetanus toxin antibody was used as a negative control and anti-HCV AR3B as a positive control. (B) Neutralization potency of AT1618 was determined by incubating HCVcc expressing E1E2 isolate JFH-1 (genotype 2a) and ED43 (genotype 4a) with a 4-fold serial dilution of purified antibody, starting at 50 μg/ml, before inoculation on Huh-7.5 cells. The neutralization percentage was determined by the reduction in luciferase activity compared to background and no antibody samples. IC₅₀ values (in μg/ml) were determined using non-linear regression analysis. Anti-HIV antibody 3BNC60 was used as a negative control and anti-HCV AR4A as a positive control. The errors bars represent 1 SD. AR3B, antibody to antigenic region 3 domain B; AR4A, antibody to antigenic region 4; HCV, hepatitis C virus; HCVcc, HCV cell culture; HIV, human immunodeficiency virus; IC₅₀, 50% inhibitory concentration; ND, not done.

Since AT1618 targets AR4, and we showed that it is able to neutralize all HCVpp from our panel, including the resistant ones, we wanted to confirm its breadth in the HCVcc system using the JFH1 prototype (genotype 2) and ED43 HCV chimera (genotype 4a). We found that AT1618 neutralized both viruses with IC₅₀ values of 0.27 μg/ml and 0.080 μg/ml, respectively (Fig. 5B and 5C).

As the expression of HCV entry factors most probably differs between Huh-7 cells and primary human hepatocytes, we repeated HCVpp neutralization experiments using primary hepatocytes. At least 1 antibody from each individual was selected for this experiment (AT1638, 1637, 1642, 1706 and 1618). As shown in Fig. 6A, at a concentration of 0.5 μg/ml, all antibodies neutralized genotype 1a H77 HCVpp infection by more than 50% using primary hepatocytes. Moreover, AT1638, 1637 and 1642 also reduced the infection of AMS 3a.26 HCVpp by more than 50% (Fig. 6B). However, AT1706 and AT1618 reduced infection of AMS 3a.26 HCVpp by 25% to 50%. This reduction was consistent with data from the neutralization experiments using Huh-7 cells, where the IC₅₀ values for AMS3a.26 HCVpp were >1.36 and 1.64 μg/ml, respectively (Fig. 4B).

Discussion

For the design of a protective HCV vaccine, a detailed understanding of the mechanism by which HCV infection is spontaneously cleared, is crucial. A strong and broad T cell response has been associated with clearance of HCV (re)infection.^{6,7} However, the role of B cells producing HCV neutralizing antibody is largely undefined. Here, we studied the B cell repertoire against HCV E1E2 in a cohort of persistent IDU following clearance of primary HCV infection. We compared the breadth of the antibodies against E1E2 early after infection between individuals who were HCV RNA negative at the end of study follow-up (CLs) and individuals who ultimately became chronically infected (CHRs). Our main finding is that the frequency of B cells producing cross-genotype antibodies was significantly higher in CLs compared to CHRs. Moreover, in a subset of 4 CLs who we studied in more detail, we found that these cross-genotype anti-

bodies mainly recognized AR3 and showed broad neutralizing activity. In addition, in 3 of these 4 CLs, we also identified cross-genotype antibodies targeting AR4.

The role of cross-neutralizing antibodies in protection against HCV infection in real-life settings has rarely been studied. Pestka *et al.* were the first to demonstrate that polyclonal serum neutralizing antibody responses were associated with spontaneous clearance of HCV infection.⁸ Recently it was shown that cross-neutralization of a genotype 1 HCVpp panel by serum from individuals infected with genotype 1 and non-1 viruses, was associated with HCV clearance.⁹ From 2 of these individuals, broadly neutralizing antibodies were isolated.³⁴ In the study presented here, a high frequency of B cells producing cross-genotype antibodies early after infection was associated with clearance of HCV infection. Moreover, in 4 of these individuals with such strong cross-genotype B cell response, we isolated broadly neutralizing antibodies. It is tempting to hypothesize that these B cells expressing broadly neutralizing antibodies were induced during infection and contributed to viral clearance.

It is important to note, however, that we do find variation in both breadth and frequency in the antibody responses between CL individuals. Participant CL5 for example presented only with genotype-specific antibodies, which could be due to the time point of PBMC selection or indicate that other components of the immune system such as T cells may have played a role in viral clearance. In addition to differences in breadth, we observed a relatively large difference in the frequency of E1E2 specific antibodies (IQR: 3.6–77 antibodies per 10,000 antibodies). This could be a consequence of the time point of PBMC selection, natural inter-donor variation or technical issues.

The longitudinal design of our study enabled the selection of a subgroup of cohort participants (CLs) who never became chronically infected, despite presumably frequent re-exposure, since they continued injecting drugs during a long period in which incidence of infection was very high in IDU.²⁰ Indeed, reinfections were documented after the time point of PBMC collection in 3 of these CLs, even though HCV RNA testing, with a median of 11 HCV RNA tests per case,²² was not performed reg-




Fig. 6. AT antibodies block entry of HCV into primary hepatocytes. The neutralization capacity of the antibodies was tested using HCVpp derived from (A) H77 HCV isolate (genotype 1), or (B) AMS3a.26 HCV isolate (genotype 3). HCVpp supernatants were incubated with 0.5 µg/ml antibody-containing B cell supernatants before being inoculated onto primary human hepatocytes seeded the day before. After 3 days, the luciferase activity was measured using an EnVision® Multilabel Reader. The anti-RSV F antibody (D25) was used as a negative control. The y-axis indicates the mean relative light units and the errors bars represent 1 SD. The grey dotted line depicts 50% of infection based on the negative control. AR3, antigenic region 3; AR4, antigenic region 4; HCV, hepatitis C virus; HCVpp, HCV pseudoparticles; RSV, respiratory syncytial virus.

ularly enough to diagnose all reinfections.³⁶ Despite this assumed frequent re-exposure, CLs were HCV RNA negative at the end of a median follow-up of 17.7 years and developed memory B cells expressing broadly neutralizing antibodies. This finding is consistent with previous reports that described memory B cells expressing broadly neutralizing antibodies, which were taken from IDUs who did not become chronically infected for more than 5 years following the clearance of primary infection.^{26,34} Importantly, we also showed that such B cell responses can be long-lasting, since memory B cells expressing broadly neutralizing antibodies were circulating 25 years after clearance of the primary infection.²⁶ In this study, we confirm the longevity of memory AR3-specific B cells as these B cells were still circulating 5.2 years after clearance of the primary infection in the CL3 participant (Fig. S7). Taken together, this suggests that broadly neutralizing antibodies induced during primary infection also contribute to the prevention of the subsequent chronic infections. However, such broadly neutralizing antibodies may not always provide sterilizing immunity, as indicated by the reinfections we observed in CLs.

The majority of antibodies with cross-reactivity against at least 3 genotypes recognized AR3. From the 4 CLs with the largest number of HCV specific B cell cultures, we isolated 8 AR3-specific monoclonal antibodies and confirmed their broadly neutralizing properties. This finding is consistent with other studies where AR3-specific antibodies have been isolated from

individuals who cleared all infections.^{26,34} The dominance of AR3-specific antibodies in the B cell repertoire from CLs suggests that these antibodies play an important role in protection against HCV infection.

Besides AR3-specific antibodies, we also detected cross-genotype antibodies targeting AR4. Little is known about AR4, since the focus has mainly been on the antibody AR4A.¹⁶ While it has been suggested that AR4-specific antibodies are rare, we observed that 27 out of 113 (24%) cross-genotype antibodies targeted AR4, and that these antibodies were present in 3 of the 4 CLs. Although less abundant than AR3 antibodies, this suggests that AR4 targeting antibodies may be present in most individuals who develop cross-reactive antibodies. However, in contrast to the broad neutralization of AR4A, only 1 out of the 4 broadly reactive monoclonal AR4-specific antibodies, isolated by us, showed broadly neutralizing capacity (AT1618). Consistent with previous observations for AR4A,¹⁶ we found that AR4-specific antibodies did not bind to the soluble E2 ectodomain, suggesting that AR4-specific antibodies only bind to the E1E2 complex or, alternatively, that a different conformation of soluble E2 precludes the binding of AR4A-like antibodies.

Several studies have shown that AR3- and AR4-specific antibodies act synergistically^{16,37} and importantly, antibodies targeting AR3 (AR3A, AR3B) protected mice against HCV infection in combination with antibody AR4A.¹⁷ Thus, our observation that 3 out of 4 CL individuals developed both AR3- and AR4-specific antibodies is interesting, since it may suggest a similarly combined neutralizing role of AR3 and AR4 specific antibodies in the clearance of HCV. If this is confirmed in future studies, a vaccine should induce antibodies against these 2 antigenic regions.

Although we did not detect antibodies recognizing all genotypes in CHRs, others did isolate broadly reactive antibodies targeting AR3 from chronically infected individuals.^{15,38} However, these antibodies were only found relatively late after infection. Here, we found that CLs had already developed B cells expressing cross-reactive antibodies within 1 year of acquiring HCV, while the CHRs at the same time point had mainly developed genotype-specific antibodies. This is in line with Osburn *et al.* who showed that the development of cross-reactive antibodies is delayed in chronically infected individuals.⁹ Interestingly, 1 CHR (CHR2) had 4 cross-reactive antibodies which were specific for only 2 to 4 genotypes (Fig. 1B). We found that those cross-reactive antibodies targeted AR3 (Fig. S8). Taken together, this suggests that in chronically infected individuals, AR3-specific antibody responses may be too weak and/or may develop too late to prevent chronic infection. If confirmed, this means that a strong and broadly neutralizing antibody response should be established very early after infection in order to confer protection.

For the early development of cross-reactive antibodies, the host genetics may also be crucial; it was shown that the early appearance of cross-reactive neutralizing antibodies was associated with 2 single nucleotide polymorphisms located upstream of the *HLA-DQB1* and *HLA-DQA2* genes.⁹

To the best of our knowledge, this is the first study comparing B cell repertoires against HCV E1E2 in individuals who spontaneously cleared ≥1 infection(s), with those in individuals who ultimately developed a chronic infection. Our data suggest that an early and strong B cell response, inducing broadly neutralizing antibodies against AR3 and AR4, is important for viral clearance and prevention of subsequent

chronic infections upon re-exposure. These observations permit cautious optimism that development of an effective preventive vaccine is feasible.

Financial support

This study was supported by the Virgo consortium, funded by the Dutch government, project number FES0908 and by the Netherlands Genomics Initiative (NGI) project number 050-060-452. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Conflicts of interest

S.J.M., C.B., D.V.B., A.Q.B., H.S. and T.B. are employees of AIMM Therapeutics and S.J.M., A.Q.B., H.S. and T.B. shareholders of AIMM Therapeutics. M.D.J. was a member of the AIMM scientific advisory board.

Please refer to the accompanying [ICMJE disclosure](#) forms for further details.

Authors' contributions

Study concept and design: Sabrina J. Merat, Menno D. de Jong, Hergen Spits, Tim Beaumont and Janke Schinkel. Study supervision: Sabrina J. Merat, Richard Molenkamp, Jonathan K. Ball, Tim Beaumont and Janke Schinkel. Funding acquisition: Jonathan K. Ball, Menno D. de Jong, Hergen Spits, Tim Beaumont and Janke Schinkel. Amsterdam Cohort Project lead and supervision: Maria Prins, Neeltje Kootstra. Acquisition of the data: Sabrina J. Merat, Camille Bru, Dorien van de Berg, Richard Molenkamp, Arjen Q. Bakker, Sylvie Koekoek (HCVcc), Alexander W. Tarr (HCVcc), Jonathan K. Ball (HCVcc). Analysis and interpretation of data: Sabrina J. Merat, Camille Bru, Dorien van de Berg, Arjen Q. Bakker, Alexander W. Tarr (HCVcc), Jonathan K. Ball (HCVcc), Tim Beaumont and Janke Schinkel (HCVcc). Drafting of manuscript: Sabrina J. Merat, Hergen Spits, Tim Beaumont and Janke Schinkel. Critical revision: Sabrina J. Merat, Alexander W. Tarr, Richard Molenkamp, Neeltje A Kootstra, Maria Prins, Jonathan K. Ball, Arjen Q. Bakker, Menno D. de Jong, Hergen Spits, Tim Beaumont and Janke Schinkel.

Acknowledgements

We would like to thank the cohort participants of the Amsterdam Cohort Studies, Margreet Bakker for the data management, Agnes Harskamp – Holwerda for sample storage and handling and all doctors and nurses of the Amsterdam Cohort Studies for data collection and blood sampling. The Amsterdam Cohort Studies on HIV infection and AIDS, a collaboration between the Amsterdam Municipal Health Service, the Academic Medical Center of the University of Amsterdam, Sanquin Blood Supply Foundation, and the Jan van Goyen Clinic, are part of the Netherlands HIV Monitoring Foundation. We also thank Dr. Jean Dubuisson for the plasmids encoding the E1E2 sequence of isolate H77, the pHCMV vector containing the MLV gag/pol and the pHCMV vector encoding the luciferase gene to set up the HCVpp assay; Dr. Koen Wagner, Yvonne Claassen and Martino Böhne for their help with antibody production and purification; Dr. Richard Urbanowicz for his advice on the HCVpp production of UKNP isolates; Ana Chumbe Mendoza for her technical help with luciferase readout; Dr. Barnabas King and Dr. Kwinten

Sliepen for supervising for HCVcc experiments and Dr. Che Colpitts for her advice on the luciferase readout of HCV infection using primary hepatocytes.

Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.jhep.2019.02.013>.

References

Author names in bold designate shared co-first authorship

- [1] World Health Organization. Global Hepatitis Report, 2017. 2017: Geneva. 2017.
- [2] Kwo PY, Poordad F, Asatryan A, Wang S, Wyles DL, Hassanein T, et al. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis. *J Hepatol* 2017;67:263–271. <https://doi.org/10.1016/j.jhep.2017.03.039>.
- [3] Dore GJ, Hatzakis A, Negro F, Waked I. Estimating HCV disease burden—volume 4 (editorial). *J Viral Hepatol* 2017;24(Suppl 2):4–7. <https://doi.org/10.1111/jvh.12763>.
- [4] Grebely J, Prins M, Hellard M, Cox AL, Osburn WO, Lauer G, et al. Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. *Lancet Infect Dis* 2012;12:408–414. [https://doi.org/10.1016/S1473-3099\(12\)70010-5](https://doi.org/10.1016/S1473-3099(12)70010-5).
- [5] Sacks-Davis R, Grebely J, Dore GJ, Osburn W, Cox AL, Rice TM, et al. Hepatitis C virus reinfection and spontaneous clearance of reinfection—the InC3 Study. *J Infect Dis* 2015;212:1407–1419. <https://doi.org/10.1093/infdis/jiv220>.
- [6] Schulze zur Wiesch J, Lauer GM, Day CL, Kim AY, Ouchi K, Duncan JE, et al. Broad repertoire of the CD4+ Th cell response in spontaneously controlled hepatitis C virus infection includes dominant and highly promiscuous epitopes. *J Immunol* 2005;175:3603–3613. <https://doi.org/10.4049/jimmunol.175.6.3603>.
- [7] Abdel-Hakeem MS, Bédard N, Murphy D, Bruneau J, Shoukry NH. Signatures of protective memory immune responses during hepatitis C virus reinfection. *Gastroenterology* 2014;147:870–878. <https://doi.org/10.1053/j.gastro.2014.07.005>.
- [8] Pestka JM, Zeisel MB, Bläser E, Schürmann P, Bartosch B, Cosset F-L, et al. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. *Proc Natl Acad Sci U S A* 2007;104:6025–6030. <https://doi.org/10.1073/pnas.0607026104>.
- [9] Osburn WO, Snider AE, Wells BL, Latanich R, Bailey JR, Thomas DL, et al. Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses. *Hepatology* 2014;59:2140–2151. <https://doi.org/10.1002/hep.27013>.
- [10] Owsianka A, Tarr AW, Juttla VS, Lavallette D, Bartosch B, Cosset F-L, et al. Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. *J Virol* 2005;79:11095–11104. <https://doi.org/10.1128/JVI.79.17.11095-11104.2005>.
- [11] Zhang P, Wu CG, Mihalik K, Virata-Theimer ML, Yu M-YW, Alter HJ, et al. Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma. *Proc Natl Acad Sci U S A* 2007;104:8449–8454. <https://doi.org/10.1073/pnas.0703039104>.
- [12] Keck Z-Y, Op De Beeck A, Hadlock KG, Xia J, Li T-K, Dubuisson J, et al. Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions. *J Virol* 2004;78:9224–9232. <https://doi.org/10.1128/JVI.78.17.9224-9232.2004>.
- [13] Desombere I, Fafi Kremer S, Van Houtte F, Pessaux P, Farhoudi A, Heydmann L, et al. Monoclonal anti-envelope antibody AP33 protects humanized mice against a patient-derived hepatitis C virus challenge. *Hepatology* 2016;63:1120–1134. <https://doi.org/10.1002/hep.28428>.
- [14] Keck Z-Y, Wang Y, Lau P, Lund G, Rangarajan S, Fauvel C, et al. Affinity maturation of a broadly neutralizing human monoclonal antibody that prevents acute HCV infection. *Hepatology* 2016. <https://doi.org/10.1002/hep.28850>.
- [15] Law M, Maruyama T, Lewis J, Giang E, Tarr AW, Stamatakis Z, et al. Broadly neutralizing antibodies protect against hepatitis C virus quasi-species challenge. *Nat Med* 2008;14:25–27. <https://doi.org/10.1038/nm1698>.

- [16] Giang E, Dorner M, Prentoe JC, Dreux M, Evans MJ, Bukh J, et al. Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. *Proc Natl Acad Sci U S A* 2012;109:6205–6210. <https://doi.org/10.1073/pnas.1114927109>.
- [17] de Jong YP, Dorner M, Mommersteeg MC, Xiao JW, Balazs AB, Robbins JB, et al. Broadly neutralizing antibodies abrogate established hepatitis C virus infection. *Sci Transl Med* 2014;6:254ra129. <https://doi.org/10.1126/scitranslmed.3009512>.
- [18] van den Hoek JA, Coutinho RA, van Haastrecht HJ, van Zadelhoff AW, Goudsmit J. Prevalence and risk factors of HIV infections among drug users and drug-using prostitutes in Amsterdam. *Aids* 1988;2:55–60.
- [19] Grebely J, Morris MD, Rice TM, Bruneau J, Cox AL, Kim AY, et al. Cohort profile: the international collaboration of incident HIV and hepatitis C in injecting cohorts (InC3) study. *Int J Epidemiol* 2013;42:1649–1659. <https://doi.org/10.1093/ije/dys167>.
- [20] van den Berg CHSB, Smit C, Bakker M, Geskus RB, Berkhout B, Jurriaans S, et al. Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users. *Eur J Epidemiol* 2007;22:183–193. <https://doi.org/10.1007/s10654-006-9089-7>.
- [21] Langendam MW, van Haastrecht HJ, van Ameijden EJ. The validity of drug users' self-reports in a non-treatment setting: prevalence and predictors of incorrect reporting methadone treatment modalities. *Int J Epidemiol* 1999;28:514–520.
- [22] Grady BPX, Prins M, Rebers S, Molenkamp R, Geskus RB, Schinkel J. BMI, male sex and IL28B genotype associated with persistently high hepatitis C virus RNA levels among chronically infected drug users up to 23 years following seroconversion. *J Viral Hepat* 2015;22:263–271. <https://doi.org/10.1111/jvh.12303>.
- [23] Murphy DG, Willems B, Deschênes M, Hilzenrat N, Mousseau R, Sabbah S. Use of sequence analysis of the NS5B region for routine genotyping of hepatitis C virus with reference to C/E1 and 5' untranslated region sequences. *J Clin Microbiol* 2007;45:1102–1112. <https://doi.org/10.1128/JCM.02366-06>.
- [24] Kwakkenbos MJ, Diehl SA, Yasuda E, Bakker AQ, van Geelen CMM, Lukens MV, et al. Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming. *Nat Med* 2010;16:123–128. <https://doi.org/10.1038/nm.2071>.
- [25] Merat SJ, van de Berg D, Bru C, Yasuda E, Breij E, Kootstra N, et al. Multiplex flow cytometry-based assay to study the breadth of antibody responses against E1E2 glycoproteins of hepatitis C virus. *J Immunol Methods* 2017. <https://doi.org/10.1016/j.jim.2017.07.015>.
- [26] Merat SJ, Molenkamp R, Wagner K, Koekkoek SM, van de Berg D, Yasuda E, et al. Hepatitis C virus broadly neutralizing monoclonal antibodies isolated 25 years after spontaneous clearance. *PLoS ONE* 2016;11. <https://doi.org/10.1371/journal.pone.0165047> e0165047.
- [27] Tarr AW, Lafaye P, Meredith L, Damier-Piolle L, Urbanowicz RA, Meola A, et al. An alpaca nanobody inhibits hepatitis C virus entry and cell-to-cell transmission. *Hepatology* 2013;58:932–939. <https://doi.org/10.1002/hep.26430>.
- [28] Gottwein JM, Jensen TB, Mathiesen CK, Meuleman P, Serre SBN, Lademann JB, et al. Development and application of hepatitis C reporter viruses with genotype 1 to 7 core-nonstructural protein 2 (NS2) expressing fluorescent proteins or luciferase in modified JFH1 NS5A. *J Virol* 2011;85:8913–8928. <https://doi.org/10.1128/JVI.00049-11>.
- [29] Wagner K, Kwakkenbos MJ, Claassen YB, Maijoor K, Böhne M, van der Sluijs KF, et al. Bispecific antibody generated with sortase and click chemistry has broad anti-influenza virus activity. *Proc Natl Acad Sci U S A* 2014;111:16820–16825. <https://doi.org/10.1073/pnas.1408605111>.
- [30] Brochet X, Lefranc MP, Giudicelli V. IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. *Nucleic Acids Res* 2008;36:W503–W508. <https://doi.org/10.1093/nar/gkn316>.
- [31] Tarr AW, Urbanowicz RA, Hamed MR, Albecka A, McClure CP, Brown RJP, et al. Hepatitis C patient-derived glycoproteins exhibit marked differences in susceptibility to serum neutralizing antibodies: genetic subtype defines antigenic but not neutralizing serotype. *J Virol* 2011;85:4246–4257. <https://doi.org/10.1128/JVI.01332-10>.
- [32] Pierce BG, Keck Z-Y, Lau P, Fauvelle C, Gowthaman R, Baumert TF, et al. Global mapping of antibody recognition of the hepatitis C virus E2 glycoprotein. *Proc Natl Acad Sci U S A* 2016;113:E6946–E6954. <https://doi.org/10.1099/vir.0.83386-0>.
- [33] Gopal R, Jackson K, Tzarum N, Kong L, Ettenger A, Guest J, et al. Probing the antigenicity of hepatitis C virus envelope glycoprotein complex by high-throughput mutagenesis. *PLoS Pathog* 2017;13. <https://doi.org/10.1371/journal.ppat.1006735> e1006735.
- [34] Bailey JR, Flyak AI, Cohen VJ, Li H, Wasilewski LN, Snider AE, et al. Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance. *JCI Insight* 2017;2. <https://doi.org/10.1172/jci.insight.92872>.
- [35] Urbanowicz RA, McClure CP, Brown RJP, Tsoleridis T, Persson MAA, Krey T, et al. A diverse panel of hepatitis C virus glycoproteins for use in vaccine research reveals extremes of monoclonal antibody neutralization resistance. *J Virol* 2015;90:3288–3301. <https://doi.org/10.1128/JVI.02700-15>.
- [36] Vickerman P, Grebely J, Dore GJ, Sacks-Davis R, Page K, Thomas DL, et al. The more you look, the more you find: effects of hepatitis C virus testing interval on reinfection incidence and clearance and implications for future vaccine study design. *J Infect Dis* 2012;205:1342–1350. <https://doi.org/10.1093/infdis/jis213>.
- [37] Carlsen THR, Pedersen J, Prentoe JC, Giang E, Keck Z-Y, Mikkelsen LS, et al. Breadth of neutralization and synergy of clinically relevant human monoclonal antibodies against HCV genotypes 1a, 1b, 2a, 2b, 2c, and 3a. *Hepatology* 2014;60:1551–1562. <https://doi.org/10.1002/hep.27298>.
- [38] Keck Z-Y, Saha A, Xia J, Wang Y, Lau P, Krey T, et al. Mapping a region of hepatitis C virus E2 that is responsible for escape from neutralizing antibodies and a core CD81-binding region that does not tolerate neutralization escape mutations. *J Virol* 2011;85:10451–10463. <https://doi.org/10.1128/JVI.05259-11>.